COVID-19, a serious pulmonary illness caused by the highly contagious novel coronavirus SARS-CoV-2, is 19 a global pandemic. COVID-19-related mortality risk factors include advanced age, male sex and certain 20 comorbidities, including immunosuppression 1 . Besides direct viral-induced injury, host cytokine-21 mediated anti-viral response potentiates tissue damage 1 . 22 Pemphigus, a mucocutaneous autoimmune blistering disease, increases infection risk via multiple 23 mechanisms, including epithelial barrier breakdown and therapy-related immunosuppression. Given the 24 need to balance appropriate pemphigus treatment with reduction of COVID-19-associated mortality risk, 25
we have outlined treatment considerations for this particularly vulnerable patient population below. 26
Rituximab, a chimeric CD20 monoclonal antibody and the only FDA-approved medication for moderate-27 to-severe pemphigus, is considered first-line therapy based on its well-documented efficacy and safety 28 profile 2 . However, its effect on B-cells is irreversible. Reconstitution of B-cell immunity can take months, 29 which could be problematic for patients who contract COVID-19. In addition, intravenous (IV) infusions 30 may not be feasible when limits on non-emergent medical care are mandated. We have taken the 31 approach of postponing rituximab infusions temporarily, with the aim of delaying peak patient 32 immunosuppression during peak COVID-19 incidence to reduce risk of adverse outcomes. 33
Besides rituximab, the mainstay of pemphigus treatment is high-dose glucocorticoids, due to their rapid 34 onset, efficacy, and low cost. However, their nonspecific immunosuppressive effects increase infection 35 risk (among other complications) in a dose-dependent manner. A basic therapeutic principle with 36 particular importance during the pandemic is that glucocorticoids and steroid-sparing 37 immunosuppressive agents such as azathioprine and mycophenolate mofetil should be tapered to the 38 lowest effective dose. In active COVID-19 infection, immunosuppressive steroid-sparing medications 39 should be discontinued, though glucocorticoid cessation often cannot be considered due to risk for 40 adrenal insufficiency. 41
Effective as adjuvant treatment in both pemphigus 3 and COVID-19 4 , IV immunoglobulin supports 42 immunity and therefore may be useful in this setting. In addition, hydroxychloroquine can be used to 43 treat pemphigus in the elderly 5 and in pregnancy and has been proposed in the treatment of Though proof of plasmapheresis efficacy is mainly anecdotal in pemphigus and COVID-19, it could also 45 be considered. The effect of convalescent plasma, an FDA-approved COVID-19 treatment under active 46 investigation, on pemphigus is unknown. 47
Emerging selective agents for pemphigus may offer certain pharmacologic advantages. For example, a 48 new oral Bruton Tyrosine Kinase inhibitor (PRN1008; currently in phase 3 clinical trials; NCT02704429) 49 works via reversible covalent binding and therefore has a self-limited immunomodulatory effect. 50
Compassionate access to this agent under these extraordinary circumstances would be very useful. In 51 addition, ofatumumab, a fully human monoclonal CD20 antibody, is shorter-acting than rituximab. 52
Despite early promise of this agent in pemphigus, a phase 3 clinical trial (NCT01920477) was 53 prematurely terminated due to changing sponsor priorities. Tocilizumab, a humanized monoclonal 54 antibody against IL-6, has been proposed to treat the inflammatory phase of COVID-19 and has been 55 reported anecdotally to help pemphigus. 56
Until sufficient experience with pemphigus and COVID-19 is available to guide therapeutic decision-57 making, we advocate for thoughtful pharmacologic selection, as well as adherence to basic infection-58 prevention principles, such as social distancing, hand-washing, and reduction of iatrogenic 59 immunosuppression as feasible.
